Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

OBJECTIVE: Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations beginning at week 2 in biological-naïve patients with PsA. METHODS: Patients were randomised (1:1) to apremilast 30 mg twice daily or placebo. At week 16, patients whose swollen and tender joint counts ha...

Full description

Saved in:
Bibliographic Details
Published in:Ann Rheum Dis
Main Authors: Nash, Peter, Ohson, Kamal, Walsh, Jessica, Delev, Nikolay, Nguyen, Dianne, Teng, Lichen, Gómez-Reino, Juan J, Aelion, Jacob A
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2018
Subjects:
Clinical and Epidemiological Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5909747/
https://ncbi.nlm.nih.gov/pubmed/29343507
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2017-211568
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items